Kater, A. P., Kersting, S., van Norden, Y., Dubois, J., Dobber, J. A., Mellink, C. H., . . . Levin, M. (2018). Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. Blood Adv.
शिकागो स्टाइल उद्धरणKater, Arnon P., et al. "Obinutuzumab Pretreatment Abrogates Tumor Lysis Risk While Maintaining Undetectable MRD for Venetoclax + Obinutuzumab in CLL." Blood Adv 2018.
एमएलए उद्धरणKater, Arnon P., et al. "Obinutuzumab Pretreatment Abrogates Tumor Lysis Risk While Maintaining Undetectable MRD for Venetoclax + Obinutuzumab in CLL." Blood Adv 2018.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.